Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Stringent response

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    143 result(s) found for: Stringent response. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2011-002081-20 Sponsor Protocol Number: 2010_52 Start Date*: 2013-05-13
    Sponsor Name:CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE
    Full Title: A Multicenter Open label Phase II study of Pomalidomide and Dexamethasone in Progressive Relapsed or Refractory Multiple Myeloma patients with deletion 17p or translocation (4;14) Adverse Karyotypi...
    Medical condition: This study will determine the efficacy and toxicity profile of pomalidomide and dexamethasone in patients with adverse prognostic factors as determined using adverse karyotypic abnormalities and th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005283-97 Sponsor Protocol Number: 2012-005 Start Date*: 2013-08-30
    Sponsor Name:Onyx Therapeutics
    Full Title: A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) AT (Completed) DE (Completed) HU (Completed) GB (Completed) IT (Completed) NL (Completed) FR (Completed) GR (Completed) PL (Completed) ES (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004007-34 Sponsor Protocol Number: HOVON87MM/NMSG18 Start Date*: 2008-11-20
    Sponsor Name:HOVON Foundation
    Full Title: Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002075-35 Sponsor Protocol Number: MK-6482-011 Start Date*: 2020-12-21
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed Aft...
    Medical condition: Renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10038409 Renal cell carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004185-34 Sponsor Protocol Number: 54767414MMY2065 Start Date*: 2019-05-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Mu...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) FR (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005034-42 Sponsor Protocol Number: MK-7684A-008 Start Date*: 2022-01-31
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezoliz...
    Medical condition: Extensive-stage small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) LT (Trial now transitioned) IE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002273-11 Sponsor Protocol Number: 54767414MMY3008 Start Date*: 2015-03-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for Hig...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) NL (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002751-34 Sponsor Protocol Number: 8050 Start Date*: 2011-10-13
    Sponsor Name:Vejle Hospital
    Full Title: An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination with Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients with Newly Di...
    Medical condition: Patients with newly diagnosed symptomatic multiple myeloma according to the International Myeloma Working Group Diagnostic Criteria (Kyle 2009)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002529-27 Sponsor Protocol Number: D5339C00001 Start Date*: 2021-02-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
    Medical condition: Advanced Cancer Whose Tumours Contain Molecular Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002879-17 Sponsor Protocol Number: 20160370 Start Date*: 2019-06-18
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006868-11 Sponsor Protocol Number: RV-MM-AMWG-407 Start Date*: 2009-02-01
    Sponsor Name:Asociación Andaluza de Hematología
    Full Title: Estudio Fase II de Combinación de Lenalidomida/Ciclofosfamida a dosis metronómicas/Prednisona para el tratamiento de pacientes mayores de 75 años con mieloma múltiple de nuevo diagnóstico
    Medical condition: Mieloma Múltiple
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001564-19 Sponsor Protocol Number: CLBH589D2222 Start Date*: 2016-04-29
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexameth...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) NO (Completed) DE (Completed) NL (Completed) HU (Completed) GR (Completed) PL (Completed) CZ (Completed) PT (Completed) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002272-88 Sponsor Protocol Number: 54767414MMY3007 Start Date*: 2014-10-20
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed) DE (Completed) BG (Completed) RO (Ongoing) PL (Completed) HR (Completed) GR (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005157-75 Sponsor Protocol Number: EMN12/HO129 Start Date*: 2015-08-06
    Sponsor Name:HOVON Foundation
    Full Title: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients
    Medical condition: Primary plasma cell leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035223 Plasma cell leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Prematurely Ended) NO (Completed) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000128-16 Sponsor Protocol Number: 2011-003 Start Date*: 2012-07-30
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002076-41 Sponsor Protocol Number: C16019 Start Date*: 2014-06-17
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
    Medical condition: Newly diagnosed multiple myeloma (NDMM) following induction therapy and autologous stem cell transplant (ASCT)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SE (Completed) DK (Completed) IT (Completed) PT (Completed) ES (Completed) AT (Completed) HU (Completed) DE (Completed) NL (Completed) GR (Completed) PL (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2016-003105-33 Sponsor Protocol Number: EMN12/HO129 Start Date*: 2017-08-02
    Sponsor Name:HOVON
    Full Title: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients
    Medical condition: Primary plasma cell leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035223 Plasma cell leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000824-32 Sponsor Protocol Number: IMDZ-04-1702 Start Date*: 2018-10-19
    Sponsor Name:Immune Design Corp.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Subjects Follo...
    Medical condition: Unresectable locally-advanced or metastatic synovial sarcoma
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001443-31 Sponsor Protocol Number: RC12_0447 Start Date*: 2013-12-30
    Sponsor Name:CHU de Nantes
    Full Title: Phase II trial studying the efficacy of a triplet combination of MLN9708, lenalidomide and dexamethasone as induction prior to, and as consolidation after high-dose therapy with peripheral stem cel...
    Medical condition: Young untreated patients with multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002485-41 Sponsor Protocol Number: EFC15951 Start Date*: 2022-08-02
    Sponsor Name:Sanofi-aventis recherche & developpement
    Full Title: A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed an...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GR (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 11:08:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA